Design, synthesis and biological activities of sorafenib derivatives as antitumor agents

Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5

Li Liu, Yichen Cao, Charles Chen et al. · Cancer Research · 2006 · 1.5K citations · Full text

Medicine, Oncology, Pharmacology +17

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

Tim Eisen, T. Ahmad, Keith T. Flaherty et al. · British Journal of Cancer · 2006 · 636 citations · Full text

Medicine, Oncology, Pharmacology +15

Discovery of<i>N</i>-(4-(3-Amino-1<i>H</i>-indazol-4-yl)phenyl)-<i>N</i>‘-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-Aminoindazole-Based Orally Active Multitargeted Receptor Tyrosine Kinase Inhibitor

Yujia Dai, Kresna Hartandi, Zhiqin Ji et al. · Journal of Medicinal Chemistry · 2007 · 185 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

Design, Synthesis, and Evaluation of Orally Active Benzimidazoles and Benzoxazoles as Vascular Endothelial Growth Factor-2 Receptor Tyrosine Kinase Inhibitors

Michele Potashman, James Bready, Angela Coxon et al. · Journal of Medicinal Chemistry · 2007 · 167 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Design and Synthesis of Orally Bioavailable Benzimidazoles as Raf Kinase Inhibitors

Savithri Ramurthy, Sharadha Subramanian, Mina Aikawa et al. · Journal of Medicinal Chemistry · 2008 · 76 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +13